The role of protein kinase C-α in malignancies of the nervous system and implications for the clinical development of the specific PKC-α inhibitor aprinocarsen (Review)

Oncology Reports

Volumn 11, Issue 2, 2004, Pages 515-522

  Lahn, Michael M ^a   Sundell, Karen L ^a   Paterson, Blake M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

'New targeted' agents; Antisense oligonucleotide; Aprinocarsen; Glioblastoma multiforme; PKC

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APRINOCARSEN; ENZYME INHIBITOR; PRKCA PROTEIN, HUMAN; PROTEIN KINASE C; PROTEIN KINASE C ALPHA;

CENTRAL NERVOUS SYSTEM TUMOR; DRUG ANTAGONISM; HUMAN; NERVOUS SYSTEM TUMOR; PATHOPHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; ENZYME INHIBITORS; HUMANS; NERVOUS SYSTEM NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA;

EID: 3242815534     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.2.515     Document Type: Review

References (69)

1. Basu A: The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 59: 257-280, 1993.
2. Couzin J: Cancer drugs. Smart weapons prove tough to design. Science 298: 522-525, 2002.
3. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334: 661-665, 1988.
4. NewtonAC: Regulation of protein kinase C. Curr Opin Cell Biol 9: 161-167, 1997.
5. Martelli AM, Sang N, Borgatti P, Capitani S and Neri LM: Multiple biological responses activated by nuclear protein kinase C. J Cell Biochem 74: 499-521, 1999. (Pubitemid 29372491)
6. Online Mendelian Inheritance in Man, OMIM TM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). URL:http://www3.ncbi.nlm.nih.gov/htbin-post/Omim/getmap?d6455, 2000.
7. O'Brian CA and Kuo JF: Protein kinase C inhibitors. In: Protein Kinase C. Kuo JF (ed). Oxford University Press, New York pp96-120, 1994.
8. O'Brian C, Vogel VG, Singletary SE and Ward NE: Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49: 3215-3217, 1989. (Pubitemid 19162127)
9. Kopp R, Noelke B, Sauter G, Schildberg FW, Paumgartner G and Pfeiffer A: Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res 51: 205-210, 1991.
10. Gescher A: Towards selective pharmacological modulation of protein kinase C - opportunities for the development of novel antineoplastic agents. Br J Cancer 66: 10-19, 1992.
11. La Porta CA, Tessitore L and Comolli R: Changes in protein kinase C alpha, delta and in nuclear beta isoform expression in tumour and lung metastatic nodules induced by diethylnitrosamine in the rat. Carcinogenesis 18: 715-719, 1997. (Pubitemid 28132458)
12. Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J and Foster CS: Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 154: 137-144, 1999. (Pubitemid 29031621)
13. Denham DW, Franz MG, Denham W, Zervos EE, Gower WR Jr, Rosemurgy AS and Norman J: Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery 124: 218-223, 1998.
14. Blobe GC, Obeid LM and Hannun YA: Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 13: 411-431, 1994.
15. Shen L, Dean NM and Glazer RI: Induction of P53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide. Mol Pharmacol 55: 396-402, 1999. (Pubitemid 29076038)
16. Wang XY, Repasky E and Liu HT: Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells. Exp Cell Res 250: 253-263, 1999. (Pubitemid 29391589)
17. Ahmad S, Trepel JB, Ohno S, Suzuki K, Tsuruo T and Glazer RI: Role of protein kinase C in the modulation of multidrug resistance: expression of the atypical gamma isoform of protein kinase C does not confer increased resistance to doxorubicin. Mol Pharmacol 42: 1004-1009, 1992. (Pubitemid 23028835)
18. Gill PK, Gescher A and Gant TW: Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta. Eur J Biochem 268: 4151-4157, 2001. (Pubitemid 32862875)
19. Swannie HC and Kaye SB: Protein kinase C inhibitors. Curr Oncol Rep 4: 37-46, 2002.
20. Gravitt KR, Ward NE, Fan D, Skibber JM, Levin B and O'Brian CA: Evidence that protein kinase C-alpha activation is a critical event in phorbol ester-induced multiple drug resistance in human colon cancer cells. Biochem Pharmacol 48: 375-381, 1994. (Pubitemid 24243981)
21. Gupta KP, Ward NE, Gravitt KR, Bergman PJ and O'Brian CA: Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J Biol Chem 271: 2102-2011, 1996.
22. Ferlay J, Bray P, Pisani P and Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1 ed. IARC CancerBase No. 5, Lyon, IARC CancerBase No. 5. IARC Press, 2001.
23. American Cancer Society: Cancer Facts and Figures: 2003. American Cancer Society, Atlanta, GA, 2003.
24. Levin V, Leibel S and Gutin P: Neoplasms of the central nervous system. In: Cancer: Principles and Practice in Oncology. 5th edition. De Vita V, Hellman S and Rosenberg S (eds). Lippincott-Raven, New York, NY, pp2022-2082, 1997.
25. Sagar S and Israel M: Tumors of the nervous system. In: Harrison's Principles of Internal Medicine. 14th edition. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL and Longo DL (eds). McGraw-Hill, New York, NY, pp2398-2409, 1998.
26. Bown N: Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol 12: 897-910, 2001.
27. Cunsolo CL, Bicocchi MP, Petti AR and Tonini GP: Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis: survival correlates with chromosome 17 status. Br J Cancer 83: 1295-1300, 2000.
28. Lastowska M, Roberts P, Pearson AD, Lewis I, Wolstenholme J and Bown N: Promiscuous translocations of chromosome arm 17q in human neuroblastomas. Genes Chromosomes Cancer 19: 143-149, 1997. (Pubitemid 27278800)
29. Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W and Dockhorn-Dworniczak B: Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol 36: 11-13, 2001.
30. Alvaro V, Levy L, Dubray C, Roche A, Peillon F, Querat B and Joubert D: Invasive human pituitary tumors express a point-mutated alpha-protein kinase-C. J Clin Endocrinol Metab 77: 1125-1129, 1993. (Pubitemid 23345456)
31. Prevostel C, Alvaro V, De Boisvilliers F, Martin A, Jaffiol C and Joubert D: The natural protein kinase C alpha mutant is present in human thyroid neoplasms. Oncogene 11: 669-674, 1995.
32. Borner C, Filipuzzi I, Weinstein IB and Imber R: Failure of wild-type or a mutant form of protein kinase C-alpha to transform fibroblasts. Nature 353: 78-80, 1991. (Pubitemid 21912461)
33. Tonini GP, Parodi MT, Di Martino D and Varesio L: Expression of protein kinase C-alpha (PKC-alpha) and MYCN MRNAs in human neuroblastoma cells and modulation during morphological differentiation induced by retinoic acid. FEBS Lett 280: 221-224, 1991.
34. Schiemann U, Assert R, Moskopp D, Gellner R, Hengst K, Gullotta F, Domschke W and Pfeiffer A: Analysis of a protein kinase C-alpha mutation in human pituitary tumours. J Endocrinol 153: 131-137, 1997. (Pubitemid 27146266)
35. Besson A and Yong VW: Involvement of P21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle progression. Mol Cell Biol 20: 4580-4590, 2000. (Pubitemid 30396106)
36. Zellner A, Fetell MR, Bruce JN, De Vivo DC and O'Driscoll KR: Disparity in expression of protein kinase C alpha in human glioma versus glioma-derived primary cell lines: therapeutic implications. Clin Cancer Res 4: 1797-1802, 1998. (Pubitemid 28304745)
37. Godfried MB, Veenstra M, Sluis P, Boon K, Asperen R, Hermus MC, Schaik BD, Voute TP, Schwab M, Versteeg R and Caron HN: The N-Myc and C-Myc downstream pathways include the chromosome 17q genes Nm23-H1 and Nm23-H2. Oncogene 21: 2097-2101, 2002. (Pubitemid 34270898)
38. Benitez-King G, Hernandez ME, Tovar R and Ramirez G: Melatonin activates PKC-alpha but not PKC-epsilon in N1E-115 cells. Neurochem Int 39: 95-102, 2001. (Pubitemid 32530634)
39. Fagerstrom S, Pahlman S, Gestblom C and Nanberg E: Protein kinase C-epsilon is implicated in neurite outgrowth in differentiating human neuroblastoma cells. Cell Growth Differ 7: 775-785, 1996. (Pubitemid 26360746)
40. Tanimukai S, Hasegawa H, Nakai M, Yagi K, Hirai M, Saito N, Taniguchi T, Terashima A, Yasuda M, Kawamata T and Tanaka C: Nanomolar amyloid beta protein activates a specific PKC isoform mediating phosphorylation of MARCKS in neuro2A cells. Neuroreport 13: 549-553, 2002. (Pubitemid 34293207)
41. Turner NA, Walker JH, Ball SG and Vaughan PF: Phorbol ester-enhanced noradrenaline secretion correlates with the presence and activity of protein kinase C-slpha in human SH-SY5Y neuroblastoma cells. J Neurochem 66: 2381-2389, 1996. (Pubitemid 26159072)
42. Yuan P, Chen G and Manji HK: Lithium activates the C-jun NH2-terminal kinases in vitro and in the CNS in vivo. J Neurochem 73: 2299-2309, 1999.
43. Zeidman R, Pettersson L, Sailaja PR, Truedsson E, Fagerstrom S, Pahlman S and Larsson C: Novel and classical protein kinase C isoforms have different functions in proliferation, survival and differentiation of neuroblastoma cells. Int J Cancer 81: 494-501, 1999. (Pubitemid 29165211)
44. Svensson K, Zeidman R, Troller U, Schultz A and Larsson C: Protein kinase C beta1 is implicated in the regulation of neuroblastoma cell growth and proliferation. Cell Growth Differ 11: 641-648, 2000. (Pubitemid 32042987)
45. Leli U, Parker PJ and Shea TB: Intracellular delivery of protein kinase C-alpha or -epsilon isoform-specific antibodies promotes acquisition of a morphologically differentiated phenotype in neuroblastoma cells. FEBS Lett 297: 91-94, 1992.
46. Parrow V, Fagerstrom S, Meyerson G, Nanberg E and Pahlman S: Protein kinase C-alpha and -epsilon are enriched in growth cones of differentiating SH-SY5Y human neuroblastoma cells. J Neurosci Res 41: 782-791, 1995.
47. Leli U, Shea TB, Cataldo A, Hauser G, Grynspan F, Beermann ML, Liepkalns VA, Nixon RA and Parker PJ: Differential expression and subcellular localization of protein kinase C alpha, beta, gamma, delta, and epsilon isoforms in SH-SY5Y neuroblastoma cells: modifications during differentiation. J Neurochem 60: 289-298, 1993. (Pubitemid 23006730)
48. Danks K, Wade JA, Batten TF, Walker JH, Ball SG and Vaughan PF: Redistribution of F-actin and large dense-cored vesicles in the human neuroblastoma SH-SY5Y in response to secretagogues and protein kinase Calpha activation. Brain Res Mol Brain Res 64: 236-245, 1999. (Pubitemid 29052474)
49. Goodall AR, Turner NA, Walker JH, Ball SG and Vaughan PF: Activation of protein kinase C-alpha and translocation of the myristoylated alanine-rich C-kinase substrate correlate with phorbol ester-enhanced noradrenaline release from SH-SY5Y human neuroblastoma cells. J Neurochem 68: 392-401, 1997. (Pubitemid 26427333)
50. Morash SC, Rose SD, Byers DM, Ridgway ND and Cook HW: Overexpression of myristoylated alanine-rich C-kinase substrate enhances activation of phospholipase D by protein kinase C in SK-N-MC human neuroblastoma cells. Biochem J 332: 321-327, 1998.
51. Rose SD, Morash SC, Ridgway DN, Byers DM and Cook HW: Overexpression of MARCKS, but not protein kinase C-alpha, increases phorbol ester-stimulated synthesis of phosphatidylcholine in human SK-N- MC neuroblastoma cells. J Neurochem 66: 1766-1769, 1996. (Pubitemid 26090581)
52. Baltuch GH, Dooley NP, Rostworowski KM, Villemure JG and Yong VW: Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. J Neurooncol 24: 241-250, 1995.
53. Lu H, Guizzetti M and Costa LG: Inorganic lead activates the mitogen-activated protein kinase kinase-mitogen-activated protein kinase-P90(RSK) signaling pathway in human astrocytoma cells via a protein kinase C-dependent mechanism. J Pharmacol Exp Ther 300: 818-823, 2002. (Pubitemid 34164984)
54. Lu H, Guizzetti M and Costa LG: Inorganic lead stimulates DNA synthesis in human astrocytoma cells: role of protein kinase Calpha. J Neurochem 78: 590-599, 2001. (Pubitemid 32729987)
55. Xiao H, Goldthwait DA and Mapstone T: The identification of four protein kinase C isoforms in human glioblastoma cell lines: PKC alpha, gamma, epsilon, and zeta. J Neurosurg 81: 734-740, 1994. (Pubitemid 24328700)
56. Chen CC: Protein kinase C alpha, delta, epsilon and zeta in C6 glioma cells. TPA induces translocation and down-regulation of conventional and new PKC isoforms but not atypical PKC zeta. FEBS Lett 332: 169-173, 1993.
57. Kaufmann R, Lindschau C, Hoer A, Henklein P, Adomeit A, Haller H, Liebmann C, Oberdisse E and Nowak G: Signaling effects of alpha-thrombin and SFLLRN in rat glioma C6 cells. J Neurosci Res 46: 641-651, 1996. (Pubitemid 26425467)
58. Jacobsson SO, Rongard E, Stridh M, Tiger G and Fowler CJ: Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 60: 1807-1813, 2000.
59. Chen CC, Cheng CS, Chang J and Huang HC: Differential correlation between translocation and down-regulation of conventional and new protein kinase C isozymes in C6 glioma cells. J Neurochem 64: 818-824, 1995.
60. Blackburn RV, Galoforo SS, Berns CM, Motwani NM, Corry PM and Lee YJ: Differential induction of cell death in human glioma cell lines by sodium nitroprusside. Cancer 82: 1137-1145, 1998. (Pubitemid 28136529)
61. Leirdal M and Sioud M: Protein kinase Calpha isoform regulates the activation of the MAP kinase ERK1/2 in human glioma cells: involvement in cell survival and gene expression. Mol Cell Biol Res Commun 4: 106-110, 2000. (Pubitemid 32183171)
62. Brodie C, Kuperstein I, Acs P and Blumberg PM: Differential role of specific PKC isoforms in the proliferation of glial cells and the expression of the astrocytic markers GFAP and glutamine synthetase. Brain Res Mol Brain Res 56: 108-117, 1998. (Pubitemid 28271667)
63. Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G, Umansky F, Lorenzo PS, Blumberg PM and Brodie C: Protein kinase Calpha and protein kinase Cdelta play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res 61: 4612-4619, 2001. (Pubitemid 32685797)
64. Shen L and Glazer RI: Induction of apoptosis in glioblastoma cells by inhibition of protein kinase C and its association with the rapid accumulation of P53 and induction of the insulin-like growth factor-1-binding protein-3. Biochem Pharmacol 55: 1711-1719, 1998. (Pubitemid 28223463)
65. Dooley NP, Baltuch GH, Groome N, Villemure JG and Yong VW: Apoptosis is induced in glioma cells by antisense oligonucleotides to protein kinase C alpha and is enhanced by cycloheximide. Neuroreport 9: 1727-1733, 1998. (Pubitemid 28289175)
66. Cho KK, Mikkelsen T, Lee YJ, Jiang F, Chopp M and Rosenblum ML: The role of protein kinase Calpha in U-87 glioma invasion. Int J Dev Neurosci 17: 447-461, 1999. (Pubitemid 29421832)
67. Ahmad S, Mineta T, Martuza RL and Glazer RI: Antisense expression of protein kinase C alpha inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 35: 904-908, 1994.
68. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL and Glazer RI: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide Mol Pharmacol 50: 236-242, 1996. (Pubitemid 26265126)
69. Patchell RA, Regine WF, Ashton P Tibbs PA, Wilson D, Shappley D and Young B: A Phase 1 trial of continuously infused intratumoral bleomycin for the treatment of eecurrent glioblastoma multiforme. J Neurooncol 60: 37-42, 2002. (Pubitemid 35153532)